For subscribers
Singapore biomedical firm to test new rapid diagnostic kit for flu
Sign up now: Get insights on Asia's fast-moving developments
Credo Biomedical's rapid diagnostics test was developed through a mixture of innovation by its research team and scientific patents that have expired and are therefore now available to all.
PHOTO: CREDO BIOMEDICAL
DeeperDive is a beta AI feature. Refer to full articles for the facts.
HONG KONG - A Singapore company believes it has moved a step nearer eliminating deaths due to complications from influenza by developing an on-the-spot test which it claims is more accurate than those currently on the market.
Credo Biomedical's rapid diagnostics test was developed through a mixture of innovation by its research team and scientific patents that have expired and are therefore now available to all.
